Imagion Biosystems has announced “Appendix 3B, New issue announcement, application for quotation of additional securities and agreement.”
Read Appendix 3B.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer